HOME
MARKET
TRADE
PRICING
PLATFORM
HELP
LOG IN
SCYNEXIS Says Second Phase 3 Study Of Ibrexafungerp On Track For Top-Line Results In Early Q2'20, Supporting NDA Submission In H2'20
Benzinga · 11/07/2019 13:04
Related